March 9, 2018 Conference
The advent of Anti-VEGF medications has revolutionized the management of wet age related macular degeneration (AMD). Instead of losing vision, most patients maintain and in some cases improve vision. But despite these advances, current therapy requires frequent injections and does not cause CNV regression. The angiogenesis cascade is complex and VEGF is only one part. There are numerous other cytokines involved in the process and using these other pathways either alone or in combination with ant-=VEGF may improve outcomes in this common blinding disease.